Fanen (Zhongshan) Biomedicine Co Ltd (Fineimmu) held the opening and strategic cooperation signing ceremony on April 15 at the National Health Technology Park in Zhongshan's Torch Development Zone.

Fineimmu was founded in September 2023 by Professor Zhou Penghui, a returned scholar from Harvard Medical School and a leading expert in next-generation cell therapy technology for solid tumors in China. The company focuses on the research and development of immunotherapy drugs for solid tumors and related business.

The company has broken through many key technical bottlenecks in immunotherapy for solid tumors and has developed multiple internationally leading cutting-edge technologies, including precise identification and isolation of autologous anti-tumor T cells.

Currently, the company has partnered up with renowned medical institutions, such as the Sun Yat-sen University Cancer Center and the Guangdong Provincial People's Hospital, to conduct tumor-related research and technology application projects.

During the signing session, Fineimmu entered into a tripartite agreement with Beihao Research Institute and Guangdong Kangze Cell Technology Co Ltd to engage in the development of world's leading novel cell therapies.